Cover Image

Glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter 2 inhibitor use among adults with diabetes mellitus by cardiovascular-kidney disease risk: National Health and Nutrition Examination Surveys, 2015-2020

Objective: Glucagon-like peptide-1 receptor agonists (GLP1-RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2Is) lower adverse cardiac and kidney events among high-risk patients with diabetes mellitus (DM) and are now guideline-recommended as first-line therapy alongside metformin. However, t...

Full description

Saved in:

Bibliographic Details
Main Authors:	Joshua A. Jacobs (Author), Alexander R. Zheutlin (Author), Catherine G. Derington (Author), Jordan B. King (Author), Ambarish Pandey (Author), Adam P. Bress (Author)
Format:	Book
Published:	Elsevier, 2024-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, anti-diabetic drugs in heart failure and cognitive impairment: potential mechanisms of the protective effects
by: Maria Antonietta Riemma, et al.
Published: (2024)

Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes
by: Vaia Lambadiari, et al.
Published: (2021)

Changes in glucose-induced plasma active glucagon-like peptide-1 levels by co-administration of sodium-glucose cotransporter inhibitors with dipeptidyl peptidase-4 inhibitors in rodents
by: Takahiro Oguma, et al.
Published: (2016)

The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study
by: Ghazwa B. Korayem, et al.
Published: (2022)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
by: Seungah Lee, et al.
Published: (2017)

Risk of major adverse limb events in patients with type 2 diabetes mellitus receiving sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based retrospective cohort study
by: Yen-Chieh Lee, et al.
Published: (2022)

Glucagon-like peptide-1 receptor agonists and derivatives in the treatment of obesity - review
by: Michal Rabenda, et al.
Published: (2024)

Glucagon-like peptide-1 (GLP-1) agonists in the treatment of obesity
by: Magdalena Mazurek, et al.
Published: (2023)

Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence
by: Emir M. Muzurović MD, MM, et al.
Published: (2022)

Pharmacoeconomic characteristics of agonists of receptors for glucagon-like peptide-1 and medicines on their base
by: I. N. Dyakov, et al.
Published: (2021)

Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
by: Laurie L. Baggio, et al.
Published: (2021)

Sodium, Glucose and Dysregulated Glucagon Secretion: The Potential of Sodium Glucose Transporters
by: Sarah L. Armour, et al.
Published: (2022)

Effect of Glucagon-like peptide-1 receptor agonists on dyslipidemia in type 2 diabetes
by: Elizabeth A. Cristiano, et al.
Published: (2020)

Impact of Glucagon-like Peptide-1 Receptor Agonists on Intestinal Epithelial Cell Barrier
by: Takizawa Y., et al.
Published: (2024)

The Therapeutic Potential of Glucagon-like Peptide 1 Receptor Agonists in Traumatic Brain Injury
by: Anja Harej Hrkać, et al.
Published: (2024)

Amelioration of muscle wasting by glucagon‐like peptide‐1 receptor agonist in muscle atrophy
by: Yeonhee Hong, et al.
Published: (2019)

Microbially produced glucagon-like peptide 1 improves glucose tolerance in mice
by: Tulika Arora, et al.
Published: (2016)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
by: Jun Tang, et al.
Published: (2022)

Inhibitors of sodium-glucose cotransporter 2: risk of ketoacidosis
by: T. M. Bukatina, et al.
Published: (2018)

Electrophilic Agonists Modulate the Transient Receptor Potential Ankyrin-1 Channels Mediated by Insulin and Glucagon-like Peptide-1 Secretion for Glucose Homeostasis
by: Marisa Jadna Silva Frederico, et al.
Published: (2023)

Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus
by: Olusola F. Onoviran, et al.
Published: (2019)

Glucagon-like peptide-1 receptor agonists for treatment of diabetes and obesity: advantage of oral delivery
by: R. R. C. New, et al.
Published: (2024)

Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials
by: Yunpeng Gu, et al.
Published: (2023)

Bibliometric and visualized analysis of sodium-Glucose cotransporter 2 inhibitors
by: He Sun, et al.
Published: (2023)

Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis
by: Xue H, et al.
Published: (2023)

Economic analysis of glucagon like peptide-1 receptor agonists from the Saudi Arabia payer perspective
by: Nimer S. Alkhatib, et al.
Published: (2022)

Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus
by: Xinrui Tan, et al.
Published: (2023)

Possible Mechanisms Underlying the Effects of Glucagon-Like Peptide-1 Receptor Agonist on Cocaine Use Disorder
by: Changliang Zhu, et al.
Published: (2022)

Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations
by: Dan Xu, et al.
Published: (2022)

The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review
by: Khang Duy Ricky Le, et al.
Published: (2024)

Risk of Fracture With Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, or Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis Combining 177 Randomized Controlled Trials With a Median Follow-Up of 26 weeks
by: Sanbao Chai, et al.
Published: (2022)

Hypersensitivity to glucagon‐like peptide‐1 receptor agonists: A case of delayed urticaria‐like rash to dulaglutide and literature review
by: Leonardo Bianchi, et al.
Published: (2024)

Glucagon-like peptide 1 (GLP-1)
by: T.D. Müller, et al.
Published: (2019)

Bibliometric Study of Sodium Glucose Cotransporter 2 Inhibitors in Cardiovascular Research
by: Lu Chen, et al.
Published: (2020)

Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection
by: Erin D. Michos, et al.
Published: (2023)

The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases
by: Cheng D, et al.
Published: (2022)

Glucagon-like peptide-1 receptor agonists: new strategies and therapeutic targets to treat atherosclerotic cardiovascular disease
by: Tianyu Wang, et al.
Published: (2024)

Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review
by: Alorfi NM, et al.
Published: (2022)

The Impact of Glucagon-Like Peptide 1 Receptor Agonists on Bone Metabolism and Its Possible Mechanisms in Osteoporosis Treatment
by: Baocheng Xie, et al.
Published: (2021)

Amelioration of inflammatory myopathies by glucagon‐like peptide‐1 receptor agonist via suppressing muscle fibre necroptosis
by: Mari Kamiya, et al.
Published: (2022)